Intignus Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.13 M
- Company Age 6 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 7.69%
- Profit Growth 25.42%
- Ebitda -8.83%
- Net Worth 118.59%
- Total Assets 67.30%
About Intignus Biotech
Intignus Biotech Private Limited (IBPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 26 June 2018 (Six years and seven months 23 days old ). Its registered office is in Pune, Maharashtra, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.13 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Gupte, Vaishnavi Kulkarni, and Nimisha Singh serve as directors at the Company.
Company Details
-
Location
Pune, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U74999PN2018PTC177401
-
Company No.
177401
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
26 Jun 2018
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Intignus Biotech?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Gupte
|
Director | 06-Jan-2021 | Current |
|
Vaishnavi Kulkarni
|
Director | 26-Jun-2018 | Current |
|
Nimisha Singh
|
Director | 29-Mar-2024 | Current |
Financial Performance of Intignus Biotech.
Intignus Biotech Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 7.69% increase. The company also saw a substantial improvement in profitability, with a 25.42% increase in profit. The company's net worth Soared by an impressive increase of 118.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Intignus Biotech?
In 2022, Intignus Biotech had a public holding of 4.61%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Accurate Diagnostics Private LimitedSanjay Gupte is a mutual person
-
Angel - Ivf LlpSanjay Gupte is a mutual person
-
Dr.Gupte Hospital Llp
Sanjay Gupte is a mutual person
-
Gestosis India Association
Sanjay Gupte is a mutual person
-
Greenarray Genomic Research & Solutions Private Limited
Sanjay Gupte is a mutual person
-
Novetrics Solutions Private Limited
Nimisha Singh is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Intignus Biotech?
Unlock and access historical data on people associated with Intignus Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Intignus Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Intignus Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
